Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
330 participants
INTERVENTIONAL
2002-06-30
2005-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pleiotropic Effects of Atorvastatin in High Cardiovascular Risk Patients
NCT01013103
Systemic Immunomodulatory Effects and Pharmacogenetics of Atorvastatin in Early Atherosclerosis
NCT00361283
To Evaluate Ezetimibe Plus Atorvastatin Versus Atorvastatin in Patients With High Cholesterol Not Controlled on Atorvastatin 20 mg (0653-079)(COMPLETED)
NCT00276458
Evaluation of Atorvastatin Treatment on Carotid Plaque.
NCT00343655
Carotid Atorvastatin Study in Hyperlipidemic Post-Menopausal Women
NCT00163163
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Blood samples
Atorvastatin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects with LDL-C \> 0.5 g/L (1.29 mmol/L) and \< 1.5 g/L (3.87 mmol/L), TG \< 4.00 g/L (4.56 mmol/L) and hs-CRP \>1.5 mg/L and \< 15 mg/L
* Subjects with a documented coronary artery disease.
Exclusion Criteria
* Subjects with secondary hyperlipidemia
* Diabetic subjects receiving insulin
* Subjects with a contra-indication to statin therapy.
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
MDS Pharma Services
INDUSTRY
Bio-Inova Life Sciences International
OTHER
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Calgary, Alberta, Canada
Pfizer Investigational Site
Edmonton, Alberta, Canada
Pfizer Investigational Site
Vancouver, British Columbia, Canada
Pfizer Investigational Site
Winnipeg, Manitoba, Canada
Pfizer Investigational Site
Halifax, Nova Scotia, Canada
Pfizer Investigational Site
London, Ontario, Canada
Pfizer Investigational Site
Oshawa, Ontario, Canada
Pfizer Investigational Site
Sarnia, Ontario, Canada
Pfizer Investigational Site
Toronto, Ontario, Canada
Pfizer Investigational Site
Weston, Ontario, Canada
Pfizer Investigational Site
Chicoutimi, Quebec, Canada
Pfizer Investigational Site
Laval, Quebec, Canada
Pfizer Investigational Site
Montreal, Quebec, Canada
Pfizer Investigational Site
Montreal, Quebec, Canada
Pfizer Investigational Site
Montreal, Quebec, Canada
Pfizer Investigational Site
Montreal, Quebec, Canada
Pfizer Investigational Site
Sherbrooke, Quebec, Canada
Pfizer Investigational Site
Ste-foy, Quebec, Canada
Pfizer Investigational Site
Saskatoon, Saskatchewan, Canada
Pfizer Investigational Site
Brno-Bohunice, , Czechia
Pfizer Investigational Site
Jindřichův Hradec, , Czechia
Pfizer Investigational Site
Prague, , Czechia
Pfizer Investigational Site
Prague, , Czechia
Pfizer Investigational Site
Prague, , Czechia
Pfizer Investigational Site
Clermont-Ferrand, Cedex, France
Pfizer Investigational Site
Langres, Cedex, France
Pfizer Investigational Site
Besançon, , France
Pfizer Investigational Site
Brest, , France
Pfizer Investigational Site
Chambéry, , France
Pfizer Investigational Site
Clamart, , France
Pfizer Investigational Site
Clermont-Ferrand, , France
Pfizer Investigational Site
Creil, , France
Pfizer Investigational Site
Dijon, , France
Pfizer Investigational Site
Évecquemont, , France
Pfizer Investigational Site
Gap, , France
Pfizer Investigational Site
Hénin-Beaumont, , France
Pfizer Investigational Site
Le Kremlin-Bicêtre, , France
Pfizer Investigational Site
Lille, , France
Pfizer Investigational Site
Marseille, , France
Pfizer Investigational Site
Metz, , France
Pfizer Investigational Site
Monaco, , France
Pfizer Investigational Site
Montpellier, , France
Pfizer Investigational Site
Mulhouse, , France
Pfizer Investigational Site
Nancy, , France
Pfizer Investigational Site
Nantes Saint Herblain, , France
Pfizer Investigational Site
Paris, , France
Pfizer Investigational Site
Paris, , France
Pfizer Investigational Site
Paris, , France
Pfizer Investigational Site
Paris, , France
Pfizer Investigational Site
Paris, , France
Pfizer Investigational Site
Pessac, , France
Pfizer Investigational Site
Poissy, , France
Pfizer Investigational Site
Pontoise, , France
Pfizer Investigational Site
Roubaix, , France
Pfizer Investigational Site
Saint-Michel, , France
Pfizer Investigational Site
Thionville, , France
Pfizer Investigational Site
Toulouse, , France
Pfizer Investigational Site
Tourcoing, , France
Pfizer Investigational Site
Vandœuvre-lès-Nancy, , France
Pfizer Investigational Site
Vandœuvre-lès-Nancy, , France
Pfizer Investigational Site
Bełchatów, , Poland
Pfizer Investigational Site
Gdynia, , Poland
Pfizer Investigational Site
Rawa Mazowiecka, , Poland
Pfizer Investigational Site
Torun, , Poland
Pfizer Investigational Site
Wroclaw, , Poland
Pfizer Investigational Site
Zamość, , Poland
Pfizer Investigational Site
Bucharest, Sector 2, Romania
Pfizer Investigational Site
Bucharest, Sector 2, Romania
Pfizer Investigational Site
Bucharest, Sector 5, Romania
Pfizer Investigational Site
Moscow, , Russia
Pfizer Investigational Site
Moscow, , Russia
Pfizer Investigational Site
Volgograd, , Russia
Pfizer Investigational Site
Bratislava, , Slovakia
Pfizer Investigational Site
Bratislava, , Slovakia
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Bonnet J, McPherson R, Tedgui A, Simoneau D, Nozza A, Martineau P, Davignon J; CAP Investigators. Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study. Clin Ther. 2008 Dec;30(12):2298-313. doi: 10.1016/j.clinthera.2008.12.023.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A2581065
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.